Boardroom Alpha
Start trial
10-Q primary document
NMTC · Quarterly Report (Form 10-Q) · Filed May 12, 2026

Neuroone Medical Technologies Corp — 10-Q exhibit

ea028890701ex10-3.htm
Neuroone Medical Technologies Corp on Boardroom Alpha

Exhibit 10.3

 

SeCOND AMENDMENT TO

Offer letter

 

THIS SECOND AMENDMENT TO OFFER LETTER (this “Second Amendment”) between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and Christopher R. Volker (the “Employee”) is entered into and made effective as of April 28, 2026 (the “Second Amendment Date”).

 

Recitals

 

Whereas, on November 10, 2023, the Company and the Employee entered into an Offer Letter (as amended by the First Amendment, as defined below, the “Offer Letter”);

 

Whereas, on September 9, 2024, the Company and the Employee entered into that certain First Amendment to Offer Letter (the “First Amendment”); and

 

Whereas, the Company and the Employee now wish to amend the Offer Letter as provided herein to be effective as of the Second Amendment Date.

 

Agreement

 

Now, Therefore, in consideration of the foregoing and the terms and conditions set forth below, the Company and the Employee hereby agree as follows:

 

1. Addition to Offer Letter.

 

(a) As of the Second Amendment Date, the 2nd paragraph of the Offer Letter is hereby deleted in its entirety and replaced with the following paragraph:

 

Beginning July 1, 2026, your position with us will be as Chief Financial Officer (the “CFO”) of the Company. In the position of CFO of the Company, you will initially report to the Company’s Chief Executive Officer (the “CEO”). You will be required to perform the duties commonly associated with the position of CFO of the Company and as may also be assigned to you from time to time by the Company’s CEO. We reserve the right to change your job title or your duties as we may reasonably decide from time to time in our sole discretion.

 

2. Construction. Unless otherwise defined herein, capitalized terms shall have the meanings set forth in the Offer Letter. The terms of this Second Amendment amend and modify the Offer Letter as if fully set forth in the Offer Letter. If there is any conflict between the terms, conditions and obligations of this Second Amendment and the Offer Letter, this Second Amendment’s terms, conditions and obligations shall control. All other provisions of the Offer Letter not specifically modified by this Second Amendment are preserved. This Second Amendment may be executed in counterparts (including via facsimile or .pdf), each of which shall be deemed an original, and all of which together shall constitute one and the same document.

 

Signatures on the Following Page

 

 

 

 

In Witness Whereof, the parties have executed this Second Amendment as of the date first written above.

 

THE EMPLOYEE:   THE COMPANY:
     
    NeuroOne Medical Technologies Corporation
     
/s/ Christopher Volker   By:   /s/ David Rosa
Christopher Volker   Name: David Rosa
    Title: Chief Executive Officer and President

 

Signature Page to

Second Amendment to Volker Offer Letter

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer